# Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

> **NCT07549451** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Phase II
- Imetelstat
- Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases

## Interventions

- **DRUG:** Imetelstat

## Key facts

- **NCT ID:** NCT07549451
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-08
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549451, "Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07549451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*